Elixiron Immunotherapeutics Inc.

Elixiron Immunotherapeutics employs advances in translational medicine to identify targets from clinical observations, and various drug modalities including biologics from phage display and single human B cell cloning platforms, to develop innovative therapies for cancer and immunological diseases. See our Pipeline of therapeutics under development below to learn more about our commitment to bring better, next-generation as well as new first-in-class immunotherapies to patients.

Pipeline

FOCUS AREA CANDIDATES

TARGET

Research

IND-enabling

Phase 1

Phase 2/3

IMMUNOLOGICAL AND DEGENERATIVE DISEASES

Indemakitug, EI-001Vitiligo; HLH

IFN-γ

AntibodyPHASE 1

Enrupatinib, EI-1071Alzheimer's disease; Tenosynovial Giant Cell Tumors

CSF1R

Small molecule inhibitorPHASE 1

CANCER

EI-012Multiple indication options

Undisclosed

AntibodyRESEARCH

EI-011Multiple indication options

Undisclosed

BifunctionalRESEARCH

EI-003Multiple indication options

Undisclosed

BifunctionalRESEARCH

mobile key1.png mobile key2.png

Team

Scientific Advisory Board

Jean-Laurent Casanova, MD PhD

Rockefeller University

Ping-Chih Ho, PhD

University of Lausanne & Ludwig Institute

Li-Fan Lu, PhD

University of California San Diego

Francisco J. Quintana, PhD

Brigham and Women’s Hospital & Harvard University

Management Team

Hung-Kai Kevin Chen, MD PhD

Chief Executive Officer and Founder

Cheng-Lung Ku, PhD

Chief Scientific Officer

Huey-Wen Helen Hsiao, PhD

Vice President of Drug Development

James Hsu, MS

Vice President, Finance & Operations

Maggie Yang, MS

Executive Director of Clinical Development

News

Elixiron Immunotherapeutics to Initiate Phase 2 Clinical Trial of Innovative Alzheimer's Drug EI-1071 at Taipei Veterans General Hospital
August 30, 2024
EI-1071, Elixiron's drug candidate targeting microglia-induced inflammation for treating Alzheimer's disease has received the approval for a clinical trial in Taiwan
September 29, 2023
EI-001, Elixiron's drug candidate for treating vitiligo, has received approval for a clinical trial in China from the National Medical Products Administration
September 10, 2023
Elixiron partners with Yang-Ming University to jointly develop new immunotherapy technology for head and neck cancer - novel drug combining tumor macrophage-targeting antibody with interleukin-10 fusion protein
August 25, 2023
A new mechanism of IFN-γ in the pathogenesis of vitiligo reveald by a discovery from the collaborative research of Chang-Gung University and Elixiron
April 25, 2023
Elixiron Immunotherapeutics Announces Orphan Drug Designation Granted to Interferon-Gamma-Neutralizing Antibody, EI 001 for the Treatment of Hemophagocytic Lymphohistiocytosis
September 6, 2022
Elixiron Immunotherapeutics Announces Orphan Drug Designation Granted to CSF-1R Inhibitor, EI-1071 for the Treatment of Idiopathic Pulmonary Fibrosis
August 2, 2022
Pathogenic autoantibodies to IFN-γ act through the impedance of receptor assembly and Fc-mediated response
July 20, 2022
Elixiron Immunotherapeutics Receives Grant from the Alzheimer’s Association to Trial Microglia-Targeting Immunotherapy
July 12, 2022
Elixiron dives into IFNγ and CSF-1R with pathway-centric approach
June 9, 2022
A bifunctional anti-PD-L1 antibody/IL-10 fusion protein targeting exhausted T cells for cancer immunotherapy
October 11, 2021
Elixiron Immunotherapeutics Closes $27 Million Series A-1 Financing Round to Progress Alzheimer’s Disease and Vitiligo Clinical-Stage Assets
August 23, 2021
Elixiron Immunotherapeutics Awarded Alzheimer’s Association Grant to Target Microglia in Alzheimer’s Disease
August 26, 2020
Taiwan Biotech and Elixiron Immunotherapeutics: Pharma Boardroom Interview
June 26, 2019
A potent and selective cFMS inhibitor EI-1071 inhibits CSF1R signaling and regulates tumor associated macrophages
September 14, 2018
Macrophage-secreted interleukin-35 regulates cancer cell plasticity to facilitate metastatic colonization
September 1, 2018

Contact

Elixiron Immunotherapeutics
16F-3, No.508, Section 7, Zhongxiao East Rd., Nangang Dist., Taipei, 115, Taiwan

Elixiron Immunotherapeutics (US office)
No. 255 Main Street, Suite 20, Cambridge, MA 02142, USA

Elixiron Immunotherapeutics (Shanghai)
02A102, Building 3, Kerry Mansion, No.118 Rongke Rd., Pudong New District, Shanghai, China

Immunometabolism Discovery Laboratory
Route de la Corniche 6, 1066, Épalinges, Switzerland

Investor inquiries: investors@elixiron.com

Media inquiries: media@elixiron.com

Careers and general inquiries: info@elixiron.com

Home
Pipeline
Team
News
Contact